RCL & Vall d’Hebron Enrols First Patient for Treatment of Pancreatic Cancer

Our first patient undergoing magnetic hyperthermia therapy using the RCL field generator.

Barcelona, March 18, 2022– The Vall d’Hebron Institute of Oncology (VHIO) has enrolled the first patient in the NoCanTher project’s clinical trial, representing an important step in bringing in nano-driven therapeutics as novel weaponry in the current arsenal of anti-cancer technologies. Specifically, this multi-center Consortium, which launched in 2016 and is powered by eleven European partners, is leading the development of magnetic nanoparticles for the treatment of locally advanced pancreatic cancer.

RCL’s magnetic hyperthermia equipment and nanoparticles are currently being using as part of the clinical study.

A full press release can be found at VHIO.